Redeye shares its view on Physitrack ahead of the preliminary trading update scheduled for 29 January, followed by the Q4 and Annual Report on 27 February. We expect the key highlights to be continued solid cash flow generation and margin improvements, despite a growth stall during the quarter.
LÄS MER
